The Immuno-oncology Drugs Market report points out national and global business prospects and competitive conditions for Immuno-oncology drugs. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Immuno-oncology drugs. The Immuno-oncology drugs market has been segmented by drug type (immune checkpoint inhibitors, monoclonal antibodies, cytokine-based immunotherapy, cancer vaccines, and car-t cell therapy), by cancer type (non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, gastric cancers, glioblastoma, and head & neck cancers). Historical background for the demand of Immuno-oncology drugs has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Immuno-oncology drugs have also been established with potential gravity. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.
By Drug Type:
- Immune Checkpoint Inhibitors
- Monoclonal Antibodies
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- and CAR-T Cell Therapy
By Cancer Type:
- Non-Small Cell Lung Cancer
- Acute Myeloid Leukemia, Lymphoma
- Multiple Myeloma
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Colorectal Cancer
- Gastric Cancers
- and Head & Neck Cancers
North America Immuno-oncology Drugs Market
- North America, by Country
- North America, by Drug Type
- North America, by Cancer Type
Europe Immuno-oncology Drugs Market
- Europe, by Country
- The Netherlands
- Rest of Europe
- Europe, by Drug Type
- Europe, by Cancer Type
Asia Pacific Immuno-oncology Drugs Market
- Asia Pacific, by Country
- South Korea
- Rest of Asia Pacific
- Asia Pacific, by Drug Type
- Asia Pacific, by Cancer Type
Middle East & Africa Immuno-oncology Drugs Market
- Middle East & Africa, by Country
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Middle East & Africa, by Drug Type
- Middle East & Africa, by Cancer Type
South America Immuno-oncology Drugs Market
- South America, by Country
- Rest of South America
- South America, by Drug Type
- South America, by Cancer Type
Major Companies: Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.
Years Covered in the Study:
Historic Year: 2017-2018
Base Year: 2019
Estimated Year: 2020
Forecast Year: 2028
Objectives of this report:
- To estimate market size for Immuno-oncology drugs market on regional and global basis.
- To identify major segments in Immuno-oncology drugs market and evaluate their market shares and demand.
- To provide a competitive scenario for the Immuno-oncology drugs market with major developments observed by key companies in the historic years.
- To evaluate key factors governing the dynamics of Immuno-oncology drugs market with their potential gravity during the forecast period.
Reasons to Buy This Report:
- Provides niche insights for decision about every possible segment helping in strategic decision making process.
- Market size estimation of the Immuno-oncology drugs market on a regional and global basis.
- A unique research design for market size estimation and forecast.
- Identification of major companies operating in the market with related developments
- Exhaustive scope to cover all the possible segments helping every stakeholder in the Immuno-oncology drugs market.
This study is customized to meet your specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
- Product Specific Competitive Analysis
For more information, contact: [email protected]